ZNO
0.065
66.7%
DUB
0.021
-44.7%
RLL
0.003
50%
CHM
0.005
-37.5%
DTR
0.052
40.5%
OFX
0.86
-34.6%
MM1
0.22
40.1%
DTZ
0.062
-28.7%
ALY
0.007
40%
CDEDC
0.005
-28.6%
ANR
0.007
40%
RDN
0.005
-28.6%
LTP
0.39
39.3%
EPX
0.021
-25%
CTO
0.004
33.3%
GTR
0.003
-25%
OVT
0.004
33.3%
DAL
0.023
-23.3%
ADO
0.009
28.6%
AUG
0.027
-20.6%
ATV
0.009
28.6%
ICG
0.004
-20%
LM1
0.165
26.9%
PHO
0.065
-18.8%
AVE
0.005
25%
PEK
0.275
-17.9%
KSN
0.115
25%
GBE
0.024
-17.2%
PPY
0.015
25%
FBR
0.005
-16.7%
RGL
0.005
25%
ARV
0.006
-14.3%
8CO
0.021
23.5%
AZL
0.006
-14.3%
JCS
0.033
22.2%
BLU
0.006
-14.3%
MRR
0.011
22.2%
ENL
0.03
-14.3%
MPK
0.6
21.2%
GLL
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BlinkLab (ASX:BB1): Partners with US based

BlinkLab (ASX:BB1) has initiated a clinical study in partnership with US based Turning Pointe Autism Foundation.

The data obtained during the course of this collaboration will be used to finalise the data collection and processing algorithms as well as AI/ML models ahead of the FDA registrational study expected to start in the second half of 2024.

BlinkLab is an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism.

Read the ASX announcement: https://yourir.info/resources/3449d9aa01a61c6b/announcements/bb1.asx/6A1205872/BB1_BlinkLab_Partnership_with_Turning_Pointe_Autism_Foundation.pdf #BB1